Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
I’ll begin by discussing adagrasib, starting with first-line non-small cell lung cancer, where we expect to share key updates across our multipronged development approach in the second half of this year.
You also saw that we received Breakthrough Therapy designation at the end of last year, which I think also speaks to the robustness of the data that we have in that third line plus setting in colorectal cancer adagrasib combined was to rituximab.